DOLISOS DOUBLES LOSS IN 1992

The French homeopathic drugs producer, Dolisos, has doubled net losses in 1992 over 1991 to 12.5 million francs ($2.3 million), despite a 2% rise in sales to 564 million francs. Operating profits, positive at 2 million francs in 1991, were negative by 8 million francs last year.

The company blames a number of "exceptional" factors, including good winter weather, lire and peseta devaluations and the "conservative accounting methods" which have been adopted by its parent company, Limagrain. Dolisos has also been fighting a commercial war with its main rival, Laboratoire Boiron, with Boiron winning most of the battles so far. Limagrain, meanwhile, has said it will bring Dolisos to break-even point this year.